CRC
AIMT

Curi RMB Capital’s Aimmune Therapeutics AIMT Stock Holding History

Curi RMB Capital’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-33,557
Closed -$703K – 766
2019
Q3 		$703K Sell
33,557
-17,502
-34% -$357K 0.02% 439
2019
Q2 		$1.06M Sell
51,059
-42,945
-46% -$884K 0.03% 402
2019
Q1 		$2.1M Buy
94,004
+46,064
+96% +$1.08M 0.05% 329
2018
Q4 		$1.15M Sell
47,940
-19,756
-29% -$511K 0.03% 472
2018
Q3 		$1.85M Sell
67,696
-12,937
-16% -$366K 0.04% 403
2018
Q2 		$2.17M Buy
80,633
+4,665
+6% +$143K 0.05% 361
2018
Q1 		$2.42M Buy
75,968
+15,530
+26% +$546K 0.06% 351
2017
Q4 		$2.29M Buy
+60,438
New +$1.95M 0.06% 355

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Curi RMB Capital's AIMT Position: Q4 2019 in Review

Curi RMB Capital sold out of Aimmune Therapeutics (AIMT) in Q4 2019, closing a stake of 33,557 shares — an estimated $703K sold.

Curi RMB Capital first reported a position in AIMT in Q4 2017 and held it in 8 quarters. The position peaked at $2.42M in Q1 2018. 155 funds tracked by Wall St. Rank hold AIMT as of Q4 2019.

  • Curi RMB Capital reported no remaining Aimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Curi RMB Capital sold 33,557 Aimmune Therapeutics shares in Q4 2019, an estimated $703K.
  • Curi RMB Capital first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 8 quarters.
  • Curi RMB Capital's Aimmune Therapeutics position peaked at $2.42M in Q1 2018.
  • 155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2019.

Based on Curi RMB Capital's 13F filing for Q4 2019, filed 13 Feb 2020.